Lung Cancer
The Challenge
A global biopharmaceutical company with multiple therapies for non-small-cell lung cancer (NSCLC) engaged DKI Health to:
Educate internal teams, many of whom were new to the lung cancer domain, about the condition.
Develop educational resources for external stakeholders, outlining the public health, societal, and economic advantages of their new medicines.
Our Solution
Defined the key questions that an educational resource on lung cancer needed to address.
Conducted research to understand the disease landscape, market and competitive situation, influential stakeholders, and other key information.
Developed a comprehensive disease profile for colleagues and established a standardized reference template adaptable to various disease domains.
Defined the value story of novel lung cancer medicines and developed the “Value of Medicines” paper on lung cancer for external stakeholders.
Benefit to Client
Internal:
Global Access to Comprehensive Resource: A centralized, comprehensive resource on lung cancer that colleagues worldwide could easily access.
Guidance for Consistent Disease Profiles: Approaches and templates for creating analogous disease profiles in various areas of interest.
Effortless Cross-Region Information Retrieval: Enabled colleagues to access information across countries and regions easily.
External
Scientific Communication on Value: A scientific paper highlighting medicines' value in lung cancer.
Amplified External Knowledge: The enhanced capacity to disseminate crucial and pertinent disease-specific information to a wide external audience.
